Comprehensive Metabolomic Profiling and Incident Cardiovascular Disease : A Systematic Review
© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley..
BACKGROUND: Metabolomics is a promising tool of cardiovascular biomarker discovery. We systematically reviewed the literature on comprehensive metabolomic profiling in association with incident cardiovascular disease (CVD).
METHODS AND RESULTS: We searched MEDLINE and EMBASE from inception to January 2016. Studies were eligible if they pertained to adult humans; followed an agnostic and/or comprehensive approach; used serum or plasma (not urine or other biospecimens); conducted metabolite profiling at baseline in the context of examining prospective disease; and included myocardial infarction, stroke, and/or CVD death in the CVD outcome definition. We identified 12 original articles (9 cohort and 3 nested case-control studies); participant numbers ranged from 67 to 7256. Mass spectrometry was the predominant analytical method. The number and chemical diversity of metabolites were very heterogeneous, ranging from 31 to >10 000 features. Four studies used untargeted profiling. Different types of metabolites were associated with CVD risk: acylcarnitines, dicarboxylacylcarnitines, and several amino acids and lipid classes. Only tiny improvements in CVD prediction beyond traditional risk factors were observed using these metabolites (C index improvement ranged from 0.006 to 0.05).
CONCLUSIONS: There are a limited number of longitudinal studies assessing associations between comprehensive metabolomic profiles and CVD risk. Quantitatively synthesizing the literature is challenging because of the widely varying analytical tools and the diversity of methodological and statistical approaches. Although some results are promising, more research is needed, notably standardization of metabolomic techniques and statistical approaches. Replication and combinations of novel and holistic methodological approaches would move the field toward the realization of its promise.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Journal of the American Heart Association - 6(2017), 10 vom: 28. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruiz-Canela, Miguel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 05.06.2018 Date Revised 02.12.2018 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/JAHA.117.005705 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM276329406 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM276329406 | ||
| 003 | DE-627 | ||
| 005 | 20231225011753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/JAHA.117.005705 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0921.xml |
| 035 | |a (DE-627)NLM276329406 | ||
| 035 | |a (NLM)28963102 | ||
| 035 | |a (PII)e005705 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruiz-Canela, Miguel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comprehensive Metabolomic Profiling and Incident Cardiovascular Disease |b A Systematic Review |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.06.2018 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. | ||
| 520 | |a BACKGROUND: Metabolomics is a promising tool of cardiovascular biomarker discovery. We systematically reviewed the literature on comprehensive metabolomic profiling in association with incident cardiovascular disease (CVD) | ||
| 520 | |a METHODS AND RESULTS: We searched MEDLINE and EMBASE from inception to January 2016. Studies were eligible if they pertained to adult humans; followed an agnostic and/or comprehensive approach; used serum or plasma (not urine or other biospecimens); conducted metabolite profiling at baseline in the context of examining prospective disease; and included myocardial infarction, stroke, and/or CVD death in the CVD outcome definition. We identified 12 original articles (9 cohort and 3 nested case-control studies); participant numbers ranged from 67 to 7256. Mass spectrometry was the predominant analytical method. The number and chemical diversity of metabolites were very heterogeneous, ranging from 31 to >10 000 features. Four studies used untargeted profiling. Different types of metabolites were associated with CVD risk: acylcarnitines, dicarboxylacylcarnitines, and several amino acids and lipid classes. Only tiny improvements in CVD prediction beyond traditional risk factors were observed using these metabolites (C index improvement ranged from 0.006 to 0.05) | ||
| 520 | |a CONCLUSIONS: There are a limited number of longitudinal studies assessing associations between comprehensive metabolomic profiles and CVD risk. Quantitatively synthesizing the literature is challenging because of the widely varying analytical tools and the diversity of methodological and statistical approaches. Although some results are promising, more research is needed, notably standardization of metabolomic techniques and statistical approaches. Replication and combinations of novel and holistic methodological approaches would move the field toward the realization of its promise | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a metabolomics | |
| 650 | 4 | |a myocardial infarction | |
| 650 | 4 | |a stroke | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Hruby, Adela |e verfasserin |4 aut | |
| 700 | 1 | |a Clish, Clary B |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Liming |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-González, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Frank B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Heart Association |d 2012 |g 6(2017), 10 vom: 28. Sept. |w (DE-627)NLM222412712 |x 2047-9980 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2017 |g number:10 |g day:28 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/JAHA.117.005705 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2017 |e 10 |b 28 |c 09 | ||